* female sex * moderate to severe covid-19 symptoms requiring hospitalization * patients requiring inpatient treatment * concurrent antiviral drugs or ongoing interventional clinical trial or any off label drug for covid-19 * patients with ongoing prostate cancer treatment * clinically significant cardiovascular disease including: * myocardial infarction within 6 months prior to registration, * uncontrolled angina within 3 months prior to registration, * congestive heart failure nyha class iii or vi * qtc interval \> 480 ms * history of clinically significant ventricular arrhythmias (e.g. ventricular tachycardia, ventricular fibrillation, torsades de pointes) * history of mobitz ii second or third degree heart block without a permanent pacemaker in place * uncontrolled hypertension as indicated by systolic blood pressure \> 170 mmhg or diastolic blood pressure \> 105 mmhg * deep venous thrombosis or pulmonary embolism within 6 months * history of cerebrovascular disease * severe concurrent disease, infection or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrolment. * known history of hiv, hepatitis b, hepatitis c * known history of seizures or any conditions that may predispose to seizure. history of loss of consciousness or ischemic cerebrovascular attack within 12 months prior to registration * concurrent anticoagulation with rivaroxaban or warfarin. concomitant and continuous use of systemic corticosteroids exceeding 10 mg/day of prednisone or a dose equivalent corticosteroid within 14 days before registration. * known hypersensitivity to enzalutamide or hypersensitivity to any of its components * any concomitant drugs contraindicated for use with enzalutamide according to the swissmedic approved product information * any psychological, familial, sociological or geographical condition potentially hampering compliance with the trial protocol and follow-up.

* female sex * moderate to severe covid-19 symptoms requiring hospitalization * patients requiring inpatient treatment * concurrent antiviral drugs or ongoing interventional clinical trial or any off label drug for covid-19 * patients with ongoing prostate cancer treatment * clinically significant cardiovascular disease including: * myocardial infarction within 6 months prior to registration, * uncontrolled angina within 3 months prior to registration, * congestive heart failure nyha class iii or vi * qtc interval \> 480 ms * history of clinically significant ventricular arrhythmias (e.g. ventricular tachycardia, ventricular fibrillation, torsades de pointes) * history of mobitz ii second or third degree heart block without a permanent pacemaker in place * uncontrolled hypertension as indicated by systolic blood pressure \> 170 mmhg or diastolic blood pressure \> 105 mmhg * deep venous thrombosis or pulmonary embolism within 6 months * history of cerebrovascular disease * severe concurrent disease, infection or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrolment. * known history of hiv, hepatitis b, hepatitis c * known history of seizures or any conditions that may predispose to seizure. history of loss of consciousness or ischemic cerebrovascular attack within 12 months prior to registration * concurrent anticoagulation with rivaroxaban or warfarin. concomitant and continuous use of systemic corticosteroids exceeding 10 mg/day of prednisone or a dose equivalent corticosteroid within 14 days before registration. * known hypersensitivity to enzalutamide or hypersensitivity to any of its components * any concomitant drugs contraindicated for use with enzalutamide according to the swissmedic approved product information * any psychological, familial, sociological or geographical condition potentially hampering compliance with the trial protocol and follow-up.

- female sex - moderate to severe covid-19 symptoms requiring hospitalization - patients requiring inpatient treatment - concurrent antiviral drugs or ongoing interventional clinical trial or any off label drug for covid-19 - patients with ongoing prostate cancer treatment - clinically significant cardiovascular disease including: - myocardial infarction within 6 months prior to registration, - uncontrolled angina within 3 months prior to registration, - congestive heart failure nyha class iii or vi - qtc interval > 480 ms - history of clinically significant ventricular arrhythmias (e.g. ventricular tachycardia, ventricular fibrillation, torsades de pointes) - history of mobitz ii second or third degree heart block without a permanent pacemaker in place - uncontrolled hypertension as indicated by systolic blood pressure > 170 mmhg or diastolic blood pressure > 105 mmhg - deep venous thrombosis or pulmonary embolism within 6 months - history of cerebrovascular disease - severe concurrent disease, infection or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrolment. - known history of hiv, hepatitis b, hepatitis c - known history of seizures or any conditions that may predispose to seizure. history of loss of consciousness or ischemic cerebrovascular attack within 12 months prior to registration - concurrent anticoagulation with rivaroxaban or warfarin. concomitant and continuous use of systemic corticosteroids exceeding 10 mg/day of prednisone or a dose equivalent corticosteroid within 14 days before registration. - known hypersensitivity to enzalutamide or hypersensitivity to any of its components - any concomitant drugs contraindicated for use with enzalutamide according to the swissmedic approved product information - any psychological, familial, sociological or geographical condition potentially hampering compliance with the trial protocol and follow-up.

- female sex - moderate to severe covid-19 symptoms requiring hospitalization - patients requiring inpatient treatment - concurrent antiviral drugs or ongoing interventional clinical trial or any off label drug for covid-19 - patients with ongoing prostate cancer treatment - clinically significant cardiovascular disease including: - myocardial infarction within 6 months prior to registration, - uncontrolled angina within 3 months prior to registration, - congestive heart failure nyha class iii or vi - qtc interval > 480 ms - history of clinically significant ventricular arrhythmias (e.g. ventricular tachycardia, ventricular fibrillation, torsades de pointes) - history of mobitz ii second or third degree heart block without a permanent pacemaker in place - uncontrolled hypertension as indicated by systolic blood pressure > 170 mmhg or diastolic blood pressure > 105 mmhg - deep venous thrombosis or pulmonary embolism within 6 months - history of cerebrovascular disease - severe concurrent disease, infection or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrolment. - known history of hiv, hepatitis b, hepatitis c - known history of seizures or any conditions that may predispose to seizure. history of loss of consciousness or ischemic cerebrovascular attack within 12 months prior to registration - concurrent anticoagulation with rivaroxaban or warfarin. concomitant and continuous use of systemic corticosteroids exceeding 10 mg/day of prednisone or a dose equivalent corticosteroid within 14 days before registration. - known hypersensitivity to enzalutamide or hypersensitivity to any of its components - any concomitant drugs contraindicated for use with enzalutamide according to the swissmedic approved product information - any psychological, familial, sociological or geographical condition potentially hampering compliance with the trial protocol and follow-up.